ResMed clears key trading range, shares hold firm between support and resistance

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-26, 12:53.

ResMed Inc. (US7611521078) remains actively traded on the NYSE, with the shares recently changing hands just below the 200 dollar mark. Technical data for 25 June 2026 show the stock oscillating between a support level at 183.58 dollars and resistance around 210.30 dollars, framing the current trading range for investors on Wall Street. TradingKey technical overview on ResMed

What the latest data show

According to a detailed technical snapshot, ResMed closed the regular session on 25 June 2026 at about 198.57 dollars, up just over 1 percent on the day, implying a market capitalization near 28.8 billion dollars at that close. TradingKey technical overview on ResMed The stock price currently trades comfortably between the identified resistance level at roughly 210.30 dollars and support at around 183.58 dollars, a band that chart watchers may treat as a range for potential swing trades. TradingKey technical overview on ResMed

The same data set assigns ResMed a price momentum score of 8.90, which ranks 63rd out of 203 companies in the broader healthcare equipment and supplies universe covered by that provider. TradingKey technical overview on ResMed Shorter and longer moving averages are mixed, with three buy signals and three sell signals across the MA5 to MA200 spectrum, underscoring a technically balanced picture for the stock at present. TradingKey technical overview on ResMed

Analyst views and sector context

Wall Street research continues to track ResMed closely alongside peers in respiratory and sleep?therapy equipment, such as Philips and Fisher & Paykel Healthcare, reflecting the company’s role in the global obstructive sleep apnea treatment market. Yahoo Finance analysis on ResMed and OSA market A recent commentary summarizing Street sentiment noted that ResMed appears among the healthcare names still favored for long?term exposure to the expanding sleep?disorder market. Yahoo Finance analysis on ResMed and OSA market

On the broker side, KeyBanc Capital Markets in late June reiterated an Overweight stance on ResMed while trimming its price target from 290 dollars to 266 dollars, citing updated valuation and growth assumptions but maintaining a positive fundamental view on the shares. Yahoo Finance summary of KeyBanc rating on ResMed That adjustment underlines that, despite modest target reductions, dedicated healthcare analysts still see the company as a core name in the sector.

The business behind the ticker

ResMed generates most of its revenue from medical devices and cloud?connected solutions used to diagnose, treat and manage sleep?disordered breathing, particularly obstructive sleep apnea in home?care settings worldwide. ResMed company overview and products A representative product line is the AirSense family of continuous positive airway pressure devices, which work with masks and digital monitoring tools to support long?term therapy adherence for patients.

Where the ResMed shares trade today

ResMed shares (US7611521078) last closed on the NYSE on 2026-06-25 at approximately 198.57 US dollars, based on available end?of?day data, with that closing level also forming the basis for the latest reported market capitalization near 28.8 billion dollars.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer to buy or sell any security. Investors should conduct their own research and consider their individual financial situation before making investment decisions.